End-to-end evidence generation & expertise
to improve Major Depressive Disorder
Major Depressive Disorder (MDD) is a leading cause of patient suffering and disability around the world. Despite the compelling, unmet need for new and more effective treatments, the development process remains challenging. At Signant, we offer study sponsors a team with the scientific expertise and global experience, as well as innovative technology, to help run successful MDD trials. Leverage our Signant SmartSignals suite to help your adult or pediatric MDD trial succeed.
Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 25 years, over 600 sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.
We Have Solutions to Help Your Study Succeed
Train and monitor raters to ensure consistency and accuracy with Rater Training and Qualification as well as Central Review services. Our experts ensure raters adhere to eligibility criteria and score diagnostic/efficacy measures correctly, and can help mitigate excessive placebo response to improve your MDD study’s data reliability.
Manage Rater Quality to Improve Data Reliability
Monitor Study Data as They Flow In
With its powerful algorithms and support from our team of experts, Signant’s Blinded Data Analytics solution improves clinical data accuracy and reliability throughout the drug development cycle. Our clinical scientists and operations experts analyze study data at all relevant levels and make recommendations for appropriate interventions.
Ensure Participant Comprehension
Signant’s robust eConsent platform employs multimedia,
managed interactions, content flagging, and virtual visits
to ensure participant comprehension of your protocol
requirements while improving site and participant
experience. Automated version control ensures the
presentation of the most recently approved ICD versions,
thus preventing a common FDA audit finding.
Maximize Signal Detection Opportunities
Talk through your MDD protocol with our science and
medicine experts, who serve as an extension of your
study team. We guide the selection and acquisition
of endpoints and assessments, advise on inclusion/
exclusion criteria, and recommend methods to decrease
site and participant burdens while improving data quality.
Simplify Assessments & Adherence for Participants
Patient-reported and clinician-reported outcome assessments are vital to fully evaluate MDD treatment risk-benefit profiles. Our eCOA solution can be tailored to sites' and patient's needs – guided assessments and built-in edit checks reduce COA errors, while alerts and reminders help improve adherence to medication dosing schedules.
Digitize Studies for End-to-end Accuracy & Visibility
While all of our solutions can be applied individually, when combined they enhance the data accuracy and operational efficiency of your MDD study. Gain immediate access to electronic data for faster decision-making and improved regulatory inspections.
24
LANGUAGES
COUNTRIES
24
9,700+
PATIENTS
4,400+
SITES
STUDIES
141
I - IV
PHASES
Our MDD Experience by the Numbers
Case Study: Central Rating & Signal Detection in MDD Trials
MDD Trial Solution Resources
Signant's Subject Matter Experts
MDD Trial Solutions
Major Depressive Disorder Clinical Research Overview
Enhance Your MDD Clinical Trials with Signant
PATIENT CONCIERGE
RTSM
eCOA
eCONSENT
LEARN MORE 🠖LEARN MORE 🠖LEARN MORE 🠖LEARN MORE 🠖
